NATCO Pharma and Lupin secured U.S.

FDA approval for Eribulin Mesylate Injection, a generic equivalent to Halaven®. This drug targets metastatic breast cancer and liposarcoma, tapping into a U.S. market with estimated annual sales of ~$363 Cr.